A common theme emerging from recent antibody research is the development and validation of advanced diagnostic tools based on antibody detection. Multiple studies highlight the creation of novel biosensors and assays designed to enhance the sensitivity, specificity, and efficiency of detecting antibodies across various diseases.
For example, researchers from Universidade Federal de Viçosa introduced a magnetoelastic wave-based biosensor for the rapid and low-cost detection of antibodies against COVID-19, which demonstrated comparable diagnostic accuracy to traditional ELISA tests. In addition to being fast to execute and having the potential for automation in large-scale diagnostic studies, the biosensor fills a significant gap in existing SARS-CoV-2 detection approaches.
Another study led by Novoa et al. developed and validated a competitive inhibition ELISA for detecting antibodies against Brucella abortus in cattle, contributing to disease control in regions where brucellosis is endemic. The developed ciELISA showed significant performance, detecting the majority of vaccinated animals as negative after 135 days and could be used for the detection of anti-B. abortus antibodies in serum samples for the brucellosis control and eradication program.
Similarly, research on neutralizing antibodies for monkeypox emphasizes high-throughput methods for identifying potent candidates that could support future diagnostic and therapeutic efforts. Researchers from Guangzhou Medical University identified three potent neutralizing antibodies with the MPXV A35 protein. They found that the IC50 of MV129 was 2.68ug/mL with authentic MPXV, was the most potent antibody.
These studies reflect a broader trend toward optimizing antibody-based diagnostics, improving accessibility, and enabling quicker responses to infectious disease outbreaks.
Biointron’s Q1 2025 annual antibody report aims to explore the events and trends of the biopharmaceutical industry in 2025 (January, February, March).
Resistance to treatment continues to limit the long-term success of many therapies. In oncology, cancers may evade antibody-based treatments through mechanisms such as antigen loss, impaired intracellular trafficking, or suppression of immune responses. To address these challenges, researchers are d
Antibody-drug conjugates (ADCs) couple the specificity of monoclonal antibodies with the cytotoxic potency of chemotherapeutic agents. Recent advances have been reported in both hematologic and solid tumors, with next-generation ADCs overcoming limitations of traditional therapies through improved t
Non–small cell lung cancer(NSCLC) remains the leading cause of cancer-related mortality worldwide. Since 2011, the U.S. Food and Drug Administration has approved over 30 new therapies for advanced NSCLC, primarily tyrosine kinase inhibitors and immune checkpoint inhibitors. Biologic age
ScientistとScience Exchangeとのご利用可能です。
